table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
infections other than COVID-19
potential COVID-19 treatments
adjuvant therapies
face mask MacIntyre ... MacIntyre ...
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment Hung IRC002 Study Team IRC005 Study Team INSIGHT FLU-IVIG ...
antiviral and associated therapy
chloroquine and derivatives CuraChik ... Peymani Borges Paton Tricou
vaccines
ebola vaccine Ishola ... EBOVAC2
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus) Sadoff
Ad26.ZEBOV () Afolabi
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine) Salisch

0 studies excluded by filtering options 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons